Payment overview · 2025
General Payments
$677.20
20 reported records · 9 companies
Healthcare provider profile · identity verified
David Edwin Kim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAGUNA BEACH, CA · NPI 1861541633
Verified facts
What the public records show
CMS Open Payments records show David Edwin Kim, MD received $677.20 in general payments during 2025 across 20 reported records.
Janssen Biotech, Inc. accounted for 36.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $244.84 | 36.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.37 | 18.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.84 | 14.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $78.09 | 11.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.74 | 5.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.32 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.24 | 3.6% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $23.07 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.69 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $677.20 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $244.84 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.37 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $94.84 | 4 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $30.32 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.24 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 222 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 204 | 55 |
| Zolpidem Tartrate | Zolpidem Tartrate | 119 | 23 |
| Alprazolam | Alprazolam | 91 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 87 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 20 |
| Doxazosin Mesylate | Doxazosin Mesylate | 83 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 16 |
| Azelastine Hcl | Azelastine Hcl | 75 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 20 |
| Lorazepam | Lorazepam | 59 | 11 |
| Tramadol Hcl | Tramadol Hcl | 59 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 14 |
| Gabapentin | Gabapentin | 50 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 45 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 45 | 11 |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Azithromycin | Azithromycin | 42 | 31 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Lisinopril | Lisinopril | 39 | 12 |
| Omeprazole | Omeprazole | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Temazepam | Temazepam | 33 | suppressed |
| Simvastatin | Simvastatin | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Eliquis | Apixaban | 27 | suppressed |
| Furosemide | Furosemide | 27 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Famotidine | Famotidine | 24 | suppressed |
| Metformin Hcl | Metformin Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Carvedilol | Carvedilol | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 13 |
| Lovastatin | Lovastatin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Ozempic | Semaglutide | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $677.20 · 20 records | Janssen Biotech, Inc. | BENLYSTA, Cologuard Collection Kit, KISUNLA, OFEV, RINVOQ, SAPHNELO, SKYRIZI, TREMFYA, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error